Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

MDRNA Buys Cequent, Signs Pfizer Pact

by Lisa M. Jarvis
April 12, 2010 | A version of this story appeared in Volume 88, Issue 15

MDRNA has agreed to buy Cequent Pharmaceuticals, a Cambridge, Mass.-based RNAi delivery firm, in an all-stock deal valued at roughly $46 million. The combined company will have multiple RNAi drug discovery platforms. It will also expand MDRNA’s oncology pipeline with a treatment for familial adenomatous polyposis, a genetic disorder that is a precursor to colon cancer. In a separate deal, MDRNA will use its dialkylated amino acid technology to formulate Pfizer’s oligonucleotides for preclinical studies. MDRNA says Pfizer is its fourth big pharma partner in recent months.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.